AEZS Aeterna Zentaris Inc.

3.35
+0  (0%)
Previous Close 3.35
Open 3.45
Price To book 10.31
Market Cap 39.09M
Shares 11,670,000
Volume 113,543
Short Ratio 1.82
Av. Daily Volume 317,163

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 data released January 4, 2017 - trial failed.
Macimorelin Acetate - Macrilen
Adult Growth Deficiency
Noted January 30, 2017 completion of Phase 3 trial with data due April 2017.
Zoptrex
Endometrial cancer

Latest News

  1. Aeterna Zentaris Announces Zoptrex™ Presentation in Prostate Cancer at 2017 Genitourinary Cancers Symposium
  2. Aeterna Zentaris Announces Plans to Pursue FDA Registration of Macrilen™
  3. Aeterna Zentaris to Present at the 2nd Annual Disruptive Growth & Healthcare Conference
  4. Aeterna Zentaris to Present at the 2017 BIO CEO and Investor Conference
  5. Drug Approvals Expected to Rise as Trump Pledges to Speed Up Approval Process: Latest Reports on AEterna Zentaris and Momenta Pharmaceuticals
  6. Expectations Run High At AEterna Zentaris Inc. (USA) (AEZS) As Two New Drugs Enter Final Testing Phases
  7. Aeterna Zentaris Announces Completion of Zoptrex™ Pivotal Phase 3 Clinical Trial in Advanced Endometrial Cancer; Expects to Report Top-Line Results in April 2017
  8. Biotech Industry Outperforming Markets in 2017: Latest Reports on Pulmatrix and Aeterna Zentaris
  9. Dryships, Agile Therapeutics in Thursday’s 52-Week Low Club
  10. AEterna Zentaris Inc. (USA) (AEZS) Is Down, But Probably Not Out
  11. 01.04.2017 Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
  12. Aeterna Zentaris Announces Top-Line Results of Confirmatory Phase 3 Trial of Macrilen™
  13. Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q3, 2016 By the Numbers : November 15, 2016
  14. Aeterna Zentaris 3Q Loss $6M or 61c/Share (AEZS)
  15. AEterna Zentaris Inc. (USA) (AEZS) Lines Up A Binary Event Reversal For The First Quarter
  16. 11.08.2016 Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results
  17. Aeterna Zentaris Reports Third Quarter 2016 Financial and Operating Results
  18. 11.01.2016 Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common Shares and Warrants
  19. Aeterna Zentaris Announces Closing of US$7,560,000 Registered Direct Offering of Common Shares and Warrants
  20. Here Are Three Big Biotech Movers And Our Take On What’s Next